Overview
Plain-language guide
An oral treatment for plaque psoriasis within the FDA-labeled population.
It blocks a specific inflammatory signal, IL-23, involved in psoriasis.
Clinical mechanism
Blocks the IL-23 receptor pathway involved in inflammatory signaling.
Applications
Human evidence
The FDA snapshot describes four randomized trials supporting the original product approval.
Tier 1Preclinical evidence
Mechanistic and preclinical findings are tracked separately and are not treated as proof of human clinical benefit.
Regulatory status
Approved. United States: Icotyde for moderate-to-severe plaque psoriasis in adults and patients aged 12 or older weighing at least 40 kg who are candidates for systemic therapy or phototherapy.
Safety
Known but Manageable Risks
- Adverse effects vary by product and indication
- Contraindications and interactions require label review
Interactions
Review the current product label and indication-specific literature for pharmacologic and absorption interactions.
Treatment pattern
Treatment patterns are product-, indication- and clinician-specific; this educational profile does not provide dosing guidance.
Manufacturing and quality
Approved-product identity, formulation and quality controls must not be extrapolated to compounded or RUO copies.
Sponsor and development history
Janssen Biotech · FDA approved. Development programs and ownership can change; confirm current sponsor disclosures.
Sources
2026-03-17: FDA approval of oral Icotyde for specified plaque psoriasis populations.
- 01FDA: Icotyde trial snapshot ↗
Regulator · 2026-03-17
Gaps and unverified claims
- Evidence must be interpreted by indication and product label.
- Approval does not establish safety or efficacy for off-label or compounded copies.
Last reviewed
September 23, 2026 (listed facts only) · Primary-source check needed